Glenmark Pharmaceuticals Ltd
NSE :GLENMARK BSE :532296 Sector : PharmaceuticalsBuy, Sell or Hold GLENMARK? Ask The Analyst
BSE
prev close
OPEN PRICE
volume
Today's low / high
52 WK low / high
bid price (qty)
offer price (qty)
NSE
prev close
open price
volume
Today's' low / high
52 WK low / high
bid price (qty)
offer price (qty)
21 Mar 1514.75 (2.43%) | 20 Mar 1478.80 (-0.53%) | 19 Mar 1486.70 (2.08%) | 18 Mar 1456.35 (1.87%) | 17 Mar 1429.60 (1.74%) | 13 Mar 1405.15 (-1.21%) | 12 Mar 1422.30 (1.58%) | 11 Mar 1400.20 (-0.21%) | 10 Mar 1403.10 (-0.09%) | 07 Mar 1404.40 (0.55%) | 06 Mar 1396.70 (0.63%) | 05 Mar 1388.00 (4.03%) | 04 Mar 1334.25 (1.60%) | 03 Mar 1313.20 (2.68%) | 28 Feb 1278.95 (-2.62%) | 27 Feb 1313.35 (-0.23%) | 25 Feb 1316.35 (-0.66%) | 24 Feb 1325.15 (1.87%) | 21 Feb 1300.80 (-3.57%) | 20 Feb 1348.95 (-1.50%) | 19 Feb 1369.45 (-0.71%) |
Technical Analysis
Short Term Investors

Very Bullish
Medium Term Investors

Neutral
Long Term Investors

Bearish
Moving Averages
5 DMA
Bullish
1472.99
10 DMA
Bullish
1439.88
20 DMA
Bullish
1385.45
50 DMA
Bullish
1426.98
100 DMA
Bullish
1501.78
200 DMA
Bearish
1513.33
Intraday Support and Resistance
(Based on Pivot Points) undefined |
Updated On Mar 21, 2025 04:00 PM For Next Trading Session
Pivots | Classic | Fibonacci | Camarilla | Woodie | DM |
---|---|---|---|---|---|
R3 | 1559.25 | 1539.05 | 1523.65 | - | - |
R2 | 1539.05 | 1526.69 | 1520.68 | 1541.06 | - |
R1 | 1526.9 | 1519.06 | 1517.72 | 1530.92 | 1532.98 |
P | 1506.7 | 1506.7 | 1506.7 | 1508.71 | 1509.74 |
S1 | 1494.55 | 1494.34 | 1511.78 | 1498.57 | 1500.63 |
S2 | 1474.35 | 1486.71 | 1508.82 | 1476.36 | - |
S3 | 1462.2 | 1474.35 | 1505.85 | - | - |
Key Metrics
EPS
81.65
P/E
18.51
P/B
1.78
Dividend Yield
0.17%
Market Cap
42,744 Cr.
Face Value
1
Book Value
848.58
ROE
-50.87%
EBITDA Growth
630.36 Cr.
Debt/Equity
0.34
Shareholding History
Quarterly Result (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Quaterly Results
Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | ||
INCOME | 2670.88 | 3860.49 | 3275.68 | 3473.21 | 3418.68 | |
PROFIT | -393.41 | -2285.2 | 340.27 | 354.21 | 347.96 | |
EPS | -12.45 | -43.17 | 12.06 | 12.55 | 12.33 |
Glenmark Pharmaceuticals Ltd Quaterly Results
Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | ||
INCOME | 1623.91 | 8081.41 | 2385.19 | 2719.18 | 2380.47 | |
PROFIT | 4.87 | 841.36 | 453.73 | 595.06 | 413.8 | |
EPS | -0.72 | 163.5 | 16.08 | 21.09 | 14.66 |
Profit & Loss (Figures in Rs. Crores)
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 6943.01 | 7721.83 | 9576.39 | 9032.11 | 10299.46 | 10705.37 | 11227.94 | 12482.71 | 12579.76 | 13246.04 | |
PROFIT | 263.52 | 743.05 | 1155.03 | 805.34 | 818.68 | 755.72 | 941.32 | 1107.67 | 609.68 | -4473.72 | |
EPS | 7.3 | 26.33 | 39.29 | 28.49 | 32.78 | 27.5 | 34.38 | 35.21 | 13.37 | -50.8 |
Glenmark Pharmaceuticals Ltd Profit & Loss
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | ||
INCOME | 5358.49 | 6306 | 8220.99 | 5709.21 | 6787.67 | 7289.2 | 8032.82 | 9202.67 | 9237.97 | 14232.55 | |
PROFIT | 1139.79 | 1484.9 | 2322 | 1016.26 | 1344.95 | 1340.12 | 1589.58 | 1643.77 | 1578.33 | 1425.03 | |
EPS | 36.72 | 52.6 | 75.86 | 35.95 | 57.49 | 48 | 58.46 | 70.8 | 42.84 | 183.11 |
Balance Sheet (Figures in Rs. Crores)
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 7,819.71 | 9,445.71 | 9,058.43 | 7,036.41 | 6,042.29 | 5,576.97 | 5,135.26 | 4,464.31 | 3,601.42 | 1,756.36 |
Total Shareholders Funds | 7,847.93 | 9,473.93 | 9,086.65 | 7,064.63 | 6,070.51 | 5,605.19 | 5,163.48 | 4,492.53 | 3,629.64 | 1,783.49 |
Minority Interest | -0.38 | 365.34 | 351.47 | -0.35 | -0.39 | -0.38 | -0.37 | -0.42 | -0.3 | -0.19 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,442.56 | 4,619.64 | 4,721.06 | 3,972.58 | 3,763.24 |
Total Debt | 1,230.93 | 4,607.88 | 3,962.02 | 4,985.72 | 4,868.63 | 4,448.67 | 4,639.38 | 4,723.65 | 3,988.11 | 3,799.93 |
Other Liabilities | 540.52 | 397.59 | 152.5 | 196.68 | 429.27 | 89.14 | 2.6 | 32.74 | 76.99 | 121.92 |
Total Liabilities | 9,619 | 14,844.74 | 13,552.64 | 12,246.68 | 11,368.02 | 10,142.62 | 9,805.09 | 9,248.5 | 7,694.44 | 5,705.15 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 9,619.64 | 10,359.59 | 10,213.47 | 8,731.58 | 8,269.83 | 6,527.27 | 5,367.95 | 4,769.92 | 4,300.54 | 3,495.47 |
Less: Accumulated Depreciation | 5,409.48 | 4,937.83 | 4,326.23 | 3,602.73 | 3,241.28 | 2,857.01 | 2,338.4 | 2,014.83 | 1,706.99 | 1,480.09 |
Net Block | 4,210.16 | 5,421.76 | 5,887.24 | 5,128.85 | 5,028.55 | 3,670.26 | 3,029.55 | 2,755.09 | 2,593.55 | 2,015.38 |
Capital Work in Progress | 661.88 | 1,189.64 | 1,009.87 | 1,381.67 | 1,221.89 | 1,398.94 | 1,121.87 | 708.11 | 542.8 | 477.13 |
Investments | 789.66 | 44.57 | 49.62 | 24.63 | 24.59 | 29.66 | 14.66 | 15.69 | 17.2 | 17.12 |
Inventories | 2,513.05 | 2,373.62 | 2,499.83 | 2,276.83 | 2,135.62 | 2,252.07 | 2,030.59 | 2,139.05 | 1,567.76 | 1,269.04 |
Sundry Debtors | 1,858.41 | 3,665.17 | 3,101.14 | 2,572.06 | 2,408.96 | 2,194.59 | 2,331.81 | 2,404.32 | 2,492.65 | 2,511.77 |
Cash and Bank Balance | 1,659.46 | 1,160.3 | 1,411.52 | 1,139.16 | 1,111.24 | 937.77 | 1,234.69 | 1,057.66 | 857.12 | 775.88 |
Loans and Advances | 1,397.17 | 3,526.44 | 1,269.87 | 1,371.54 | 1,147.78 | 1,312.4 | 1,391.61 | 1,273.61 | 986.77 | 774.38 |
Total Current Assets | 7,428.08 | 10,725.53 | 8,282.35 | 7,359.58 | 6,803.61 | 6,696.83 | 6,988.69 | 6,874.64 | 5,904.3 | 5,331.07 |
Current Liabilities | 3,807.27 | 3,935.93 | 2,914.64 | 2,763.7 | 2,744.43 | 2,662.08 | 2,357.82 | 2,252.41 | 2,364.42 | 2,334.38 |
Provisions | 932.08 | 590.51 | 584.5 | 564.45 | 555.91 | 484.11 | 432.46 | 262.95 | 134.03 | 216.78 |
Total Current Liabilities & Provisions | 4,739.35 | 4,526.44 | 3,499.14 | 3,328.16 | 3,300.34 | 3,146.18 | 2,790.28 | 2,515.36 | 2,498.44 | 2,551.16 |
Net Current Assets | 2,688.74 | 6,199.09 | 4,783.21 | 4,031.42 | 3,503.27 | 3,550.65 | 4,198.41 | 4,359.27 | 3,405.86 | 2,779.91 |
Deferred Tax Assets | 1,049.72 | 1,805.91 | 1,969.55 | 1,852.18 | 1,770.85 | 1,761.63 | 1,728.58 | 1,553.35 | 1,274.96 | 169.73 |
Deferred Tax Liability | 0.28 | 0.51 | 314.93 | 346.26 | 331.59 | 378.68 | 408.32 | 242.08 | 210.07 | 222.52 |
Net Deferred Tax | 1,049.44 | 1,805.4 | 1,654.62 | 1,505.92 | 1,439.26 | 1,382.95 | 1,320.26 | 1,311.27 | 1,064.89 | -52.79 |
Other Assets | 219.11 | 184.27 | 168.08 | 174.18 | 150.45 | 110.16 | 120.34 | 99.06 | 70.15 | 468.42 |
Total Assets | 9,618.99 | 14,844.73 | 13,552.65 | 12,246.67 | 11,368.01 | 10,142.61 | 9,805.09 | 9,248.49 | 7,694.44 | 5,705.16 |
Contingent Liabilities | 1,063.3 | 336.69 | 361.31 | 384.2 | 271.21 | 73.51 | 47.1 | 36.88 | 36.89 | 129.37 |
Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
SOURCES OF FUNDS : | ||||||||||
Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | 27.13 |
Reserves Total | 22,942.4 | 17,849.25 | 16,710.37 | 14,781.29 | 13,198.05 | 11,913.87 | 10,363.22 | 9,408.4 | 7,337.75 | 4,924.92 |
Total Shareholders Funds | 22,970.62 | 17,877.47 | 16,738.59 | 14,809.51 | 13,226.27 | 11,942.09 | 10,391.44 | 9,436.62 | 7,365.97 | 4,952.05 |
Secured Loans | 0 | 0 | 0 | 0 | 0 | 6.11 | 19.74 | 2.59 | 15.53 | 36.69 |
Unsecured Loans | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,128.37 | 2,961.33 | 2,773.94 | 771.89 | 373.41 |
Total Debt | 707.29 | 3,221.22 | 3,737.7 | 3,703.99 | 3,573.76 | 3,134.48 | 2,981.07 | 2,776.53 | 787.42 | 410.1 |
Other Liabilities | 131.94 | 372.58 | 121.32 | 136.61 | 205.65 | 88.51 | 2.6 | 2.41 | 4.7 | 121.92 |
Total Liabilities | 23,809.85 | 21,471.27 | 20,597.61 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.09 | 5,484.07 |
APPLICATION OF FUNDS : | ||||||||||
Gross Block | 3,392.75 | 3,183.65 | 3,026.28 | 2,848.56 | 2,595.06 | 2,260.1 | 2,581.75 | 2,368.53 | 2,107.04 | 1,801.98 |
Less : Accumulated Depreciation | 1,636.5 | 1,437.7 | 1,273.95 | 1,126.07 | 983.11 | 846.62 | 882.63 | 772.16 | 669.04 | 571.3 |
Net Block | 1,756.25 | 1,745.95 | 1,752.33 | 1,722.49 | 1,611.95 | 1,413.48 | 1,699.12 | 1,596.37 | 1,438 | 1,230.68 |
Capital Work in Progress | 197.67 | 172.34 | 109.04 | 131.4 | 200.01 | 286.2 | 419.68 | 270.66 | 276.06 | 294.19 |
Investments | 12,964.79 | 10,332.71 | 8,559.39 | 6,989.95 | 4,713.93 | 3,268.75 | 3,212.68 | 1,866.7 | 1,858.43 | 1,659.52 |
Inventories | 1,142.69 | 1,090.21 | 951.66 | 762.39 | 837.5 | 911.21 | 1,111.18 | 1,145.06 | 968 | 736.63 |
Sundry Debtors | 2,484.47 | 2,505.66 | 2,678.32 | 2,488.75 | 1,835.24 | 2,087.13 | 3,828.91 | 3,879.4 | 3,057.66 | 2,440.83 |
Cash and Bank Balance | 129.15 | 93.79 | 29.63 | 15.79 | 88.26 | 256.48 | 177.38 | 252.18 | 74.24 | 48.55 |
Loans and Advances | 925.17 | 696.82 | 743.31 | 1,642.2 | 1,662.89 | 1,886.33 | 757.78 | 674.19 | 528.03 | 371.94 |
Total Current Assets | 4,681.48 | 4,386.48 | 4,402.93 | 4,909.12 | 4,423.89 | 5,141.15 | 5,875.25 | 5,950.83 | 4,627.93 | 3,597.95 |
Current Liabilities | 3,249.79 | 2,952.14 | 2,168.39 | 1,834.31 | 1,827.48 | 1,855.86 | 1,796.56 | 1,727.02 | 1,867.56 | 1,882.99 |
Provisions | 354.74 | 162.52 | 148.49 | 133.11 | 118.45 | 121.75 | 93.2 | 57.97 | 87.37 | 151.38 |
Total Current Liabilities & Provisions | 3,604.54 | 3,114.66 | 2,316.88 | 1,967.41 | 1,945.92 | 1,977.62 | 1,889.76 | 1,784.98 | 1,954.93 | 2,034.37 |
Net Current Assets | 1,076.94 | 1,271.82 | 2,086.05 | 2,941.71 | 2,477.97 | 3,163.54 | 3,985.49 | 4,165.85 | 2,672.99 | 1,563.58 |
Deferred Tax Assets | 475.61 | 1,160.25 | 1,137.47 | 1,118.72 | 1,081.34 | 1,063.23 | 1,056.45 | 820.62 | 589.41 | 24.84 |
Deferred Tax Liability | 309.77 | 213.5 | 214.2 | 265.43 | 276.6 | 351.1 | 395.83 | 226.56 | 188.25 | 157.23 |
Net Deferred Tax | 165.84 | 946.75 | 923.27 | 853.29 | 804.74 | 712.13 | 660.62 | 594.06 | 401.16 | -132.39 |
Other Assets | 7,648.37 | 7,001.7 | 7,167.54 | 6,011.27 | 7,197.08 | 6,320.98 | 3,397.52 | 3,721.92 | 1,511.43 | 868.49 |
Total Assets | 23,809.85 | 21,471.26 | 20,597.62 | 18,650.11 | 17,005.68 | 15,165.08 | 13,375.11 | 12,215.56 | 8,158.08 | 5,484.07 |
Contingent Liabilities | 2,658.49 | 3,443.3 | 3,325.06 | 3,730.17 | 4,430.59 | 3,680.94 | 4,549.6 | 3,720.76 | 4,594.01 | 5,326.65 |
Cash Flow (Figures in Rs. Crores)
Net Profit before Tax and Extr... | 569.19 |
Depreciation | 630.81 |
Interest (Net) | 500.14 |
P/L on Sales of Assets | -0.83 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 68.38 |
P/L in Forex | -342.59 |
Total Adjustments (PBT and Ext... | 1,009.81 |
Operating Profit before Workin... | 1,579 |
Trade and 0ther Receivables | 969.51 |
Inventories | -513.86 |
Trade Payables | -734.41 |
Total Adjustments (OP before W... | -796.95 |
Cash Generated from/(used in) ... | 782.05 |
Direct Taxes Paid | -1,047.49 |
Total Adjustments(Cash Generat... | -1,047.49 |
Cash Flow before Extraordinary... | -265.44 |
Net Cash from Operating Activi... | -265.44 |
Purchased of Fixed Assets | -898.38 |
Sale of Fixed Assets | 2.08 |
Sale of Investments | 7.05 |
Interest Received | 17.16 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 4,386.82 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 481.12 |
Of the Long Tem Borrowings | -3,649.49 |
Of Financial Liabilities | -104.43 |
Dividend Paid | -117.75 |
Interest Paid | -516.78 |
Net Cash used in Financing Act... | -3,906.13 |
Net Profit before Tax and Extr... | 7,000.75 |
Depreciation | 202.16 |
Interest (Net) | 103.58 |
Dividend Received | 228.39 |
P/L on Sales of Assets | 0.25 |
P/L on Sales of Invest | -7.05 |
Prov. and W/O (Net) | 33.39 |
P/L in Forex | -173.41 |
Total Adjustments (PBT and Ext... | -5,884.79 |
Operating Profit before Workin... | 1,115.96 |
Trade and 0ther Receivables | -63.2 |
Inventories | -147.52 |
Trade Payables | -272.03 |
Total Adjustments (OP before W... | -740.31 |
Cash Generated from/(used in) ... | 375.65 |
Direct Taxes Paid | -871.1 |
Total Adjustments(Cash Generat... | -871.1 |
Cash Flow before Extraordinary... | -495.45 |
Net Cash from Operating Activi... | -495.45 |
Purchased of Fixed Assets | -195.11 |
Sale of Fixed Assets | 0.5 |
Sale of Investments | 7.05 |
Interest Received | 278.45 |
Invest.In Subsidiaires | -9.05 |
Loans to Subsidiaires | -2,562.51 |
Cancellation of Investment in ... | 5,449.61 |
Net Cash used in Investing Act... | 3,197.17 |
Proceeds from Issue of shares ... | 1.2 |
Proceed from Short Tem Borrowi... | 150 |
Of the Long Tem Borrowings | -2,449.18 |
Of Financial Liabilities | -35.63 |
Dividend Paid | -70.45 |
Interest Paid | -262.39 |
Net Cash used in Financing Act... | -2,666.45 |
Company Details
Registered Office |
|
Address | B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Registrars |
|
Address | B/2 Mahalaxmi Chambers |
City | Mumbai |
State | Maharashtra |
Pin Code | 400026 |
Tel. No. | 91-22-40189999 |
Fax. No. | 91-22-40189986 |
complianceofficer@glenmarkpharma.com | |
Internet | http://www.glenmarkpharma.com |
Management |
|
Name | Designation |
Glenn Saldanha | Chairman & Managing Director |
Cheryl Pinto | Executive Director (Corporate) |
V S Mani | Executive Director & Group CFO |
B E Saldanha | Non Executive Director |
Rajesh Desai. | Independent Non Exe. Director |
Sona Saira Ramasastry | Independent Non Exe. Director |
Dipankar Bhattacharjee | Independent Non Exe. Director |
V R Iyer | Independent Non Exe. Director |
Pradeep Kumar Sinha | Additional Director |